Fmr LLC Has $114,000 Stock Holdings in Pediatrix Medical Group, Inc. (NYSE:MD)

Fmr LLC raised its position in Pediatrix Medical Group, Inc. (NYSE:MD) by 220.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,841 shares of the company’s stock after buying an additional 6,771 shares during the quarter. Fmr LLC’s holdings in Pediatrix Medical Group were worth $114,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Rubric Capital Management LP boosted its stake in shares of Pediatrix Medical Group by 797.0% during the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock valued at $61,532,000 after purchasing an additional 7,241,400 shares in the last quarter. Dana Investment Advisors Inc. raised its stake in Pediatrix Medical Group by 80.3% during the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock worth $7,725,000 after buying an additional 455,785 shares during the period. Cubist Systematic Strategies LLC boosted its holdings in Pediatrix Medical Group by 639.4% in the second quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock worth $2,192,000 after acquiring an additional 251,072 shares in the last quarter. ClariVest Asset Management LLC bought a new stake in Pediatrix Medical Group during the 2nd quarter valued at $1,721,000. Finally, Algert Global LLC acquired a new stake in shares of Pediatrix Medical Group in the 3rd quarter worth about $1,315,000. 97.71% of the stock is currently owned by institutional investors.

Pediatrix Medical Group Trading Down 1.1 %

NYSE:MD opened at $14.09 on Monday. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -4.60, a PEG ratio of 2.00 and a beta of 1.57. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. The company’s 50 day moving average price is $14.19 and its 200-day moving average price is $10.99. Pediatrix Medical Group, Inc. has a 52 week low of $6.62 and a 52 week high of $16.41.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.37 by $0.07. The company had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. Pediatrix Medical Group’s revenue for the quarter was up .9% on a year-over-year basis. During the same period last year, the company earned $0.29 EPS. On average, equities research analysts forecast that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current fiscal year.

Insider Buying and Selling at Pediatrix Medical Group

In related news, Director Mark S. Ordan sold 27,600 shares of the stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the sale, the director now directly owns 138,683 shares of the company’s stock, valued at approximately $2,128,784.05. This represents a 16.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Mary Ann E. Moore sold 8,108 shares of Pediatrix Medical Group stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $129,728.00. Following the transaction, the executive vice president now directly owns 135,810 shares in the company, valued at $2,172,960. This represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. 2.00% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft boosted their target price on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Macquarie began coverage on shares of Pediatrix Medical Group in a report on Monday, December 16th. They set an “outperform” rating and a $18.00 target price on the stock. Truist Financial upped their price objective on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. UBS Group upped their target price on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, Jefferies Financial Group lifted their target price on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $16.42.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.